Regaining compliance with Nasdaq's minimum bid price listing requirement is a positive development for Bionano Genomics. It removes the risk of delisting, which could have had a negative impact on the company's stock price. This news could boost investor confidence in the company, potentially leading to an increase in the stock price in the short term.